143 related articles for article (PubMed ID: 35017453)
1. Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure.
Jacobs TG; van Aerde KJ; Colbers A; Burger DM
Pediatr Infect Dis J; 2022 Feb; 41(2):131-132. PubMed ID: 35017453
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.
Liu XI; Momper JD; Rakhmanina NY; Green DJ; Burckart GJ; Cressey TR; Mirochnick M; Best BM; van den Anker JN; Dallmann A
Clin Pharmacokinet; 2020 Nov; 59(11):1433-1450. PubMed ID: 32451908
[TBL] [Abstract][Full Text] [Related]
3. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
[TBL] [Abstract][Full Text] [Related]
6. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study.
Money D; Lee T; O'Brien C; Brophy J; Bitnun A; Kakkar F; Boucoiran I; Alimenti A; Vaudry W; Singer J; Sauve LJ;
BJOG; 2019 Oct; 126(11):1338-1345. PubMed ID: 31188522
[TBL] [Abstract][Full Text] [Related]
7. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Blackman AL; Heil EL; Devanathan AS; Pandit NS
Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
[TBL] [Abstract][Full Text] [Related]
9. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
Feng HP; Guo Z; Ross LL; Fraser I; Panebianco D; Jumes P; Fandozzi C; Caro L; Talaty J; Ma J; Mangin E; Huang X; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
J Antimicrob Chemother; 2019 Mar; 74(3):710-717. PubMed ID: 30541077
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy.
Chaudhary S; Nair AB; Shah J; Gorain B; Jacob S; Shah H; Patel V
AAPS PharmSciTech; 2021 Apr; 22(3):127. PubMed ID: 33835317
[TBL] [Abstract][Full Text] [Related]
11. Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir" by Calza
Ciccullo A; Baldin G; Borghi V; Lassandro AP; Farinacci D; Guaraldi G; Mussini C; Di Giambenedetto S
AIDS Res Hum Retroviruses; 2021 May; 37(5):333-334. PubMed ID: 33587009
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J;
Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.
Massud I; Martin A; Dinh C; Mitchell J; Jenkins L; Heneine W; Pau CP; García-Lerma JG
J Antimicrob Chemother; 2015 May; 70(5):1473-81. PubMed ID: 25630643
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV.
Kreutzwiser D; Sheehan N; Dayneka N; Lemire B; Wong A; Samson L; Brophy J
Antivir Ther; 2017; 22(6):545-549. PubMed ID: 28198351
[TBL] [Abstract][Full Text] [Related]
15.
Mathew JM; Mpangase PT; Sengupta D; Kwenda S; Mavri-Damelin D; Ramsay M
Pharmacogenomics; 2021 Oct; 22(15):963-972. PubMed ID: 34528449
[No Abstract] [Full Text] [Related]
16. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Single-Dose Versus Double-Dose Dolutegravir After Switching From a Failing Efavirenz-Based Regimen.
Griesel R; Banda CG; Zhao Y; Omar Z; Wiesner L; Meintjes G; Sinxadi P; Maartens G
J Acquir Immune Defic Syndr; 2024 May; 96(1):85-91. PubMed ID: 38372621
[TBL] [Abstract][Full Text] [Related]
18. Clinical Trials That Have Changed Clinical Practice and Care of Pregnant People With HIV.
Fisher SA; Madden N; Espinal M; Garcia PM; Jao JK; Yee LM
Clin Obstet Gynecol; 2024 Jun; 67(2):381-398. PubMed ID: 38450526
[TBL] [Abstract][Full Text] [Related]
19. Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa.
Mpofu R; Kawuma AN; Wasmann RE; Akpomiemie G; Chandiwana N; Sokhela SM; Moorhouse M; Venter WDF; Denti P; Wiesner L; Post FA; Haas DW; Maartens G; Sinxadi P
Br J Clin Pharmacol; 2024 May; 90(5):1247-1257. PubMed ID: 38332460
[TBL] [Abstract][Full Text] [Related]
20. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
